Abstract
4033 Background: The standard treatment for advanced HCC is sorafenib. However this treatment does not induce tumor shrinkage and allows a modest improvement in overall survival (OS) and progression-free survival (PFS). For 10 years, we have developed a regimen of combined systemic chemotherapy with gemcitabine and oxaliplatin (GemOx regimen) which provides adequate control of the disease with manageable toxicity. We report our experience on > 200 patients (pts) consecutively treated with this regimen. Methods: This retrospective multicenter study included all consecutive pts treated for advanced HCC with GemOx. Survival curves were drawn with the Kaplan-Meier method and compared by the log-rank test. Models of univariate and multivariate analyses were used to search for prognostic and predictive factors of therapeutic efficacy and OS. Results: 210 pts were enrolled from 2001 to 2010. 190 pts are currently with complete data collection. Average age: 60 years (20-83), M / F: 164/26, metastatic stage: 36%, underlying cirrhosis: 86%, Child Pugh score A: 75 % B: 21%, C: 4%, median CLIP score: 3 (0-5), WHO Performance status 0/1/2/3: 34/49/15/2 %. The objective response rate (OR: complete response + partial response) was 21% (WHO criteria) and disease control rate (DCR: OR + stable disease) was 62 %. The median PFS and OS were 6 (95% CI: 4.5 to 10) and 10.5 (95% CI: 9-13) months, respectively. Ten pts were eligible for curative surgery and 5 for secondary
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
